Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Pembrolizumab clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention. Browse Pembrolizumab recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1844
Shown on this page
12
Current sort
Recently updated
Therapy scope
Pembrolizumab
Additional filters apply within this therapy.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this therapy

These controls apply only within Pembrolizumab. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 109–120 of 1,844 matching trials for Pembrolizumab.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Not yet recruiting Phase 3 Interventional

Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer

NCT07867002
View directory record Official record
Conditions
Endometrial Adenocarcinoma, Metastatic Endometrial Cancer, Endometrial Cancer, Recurrent Endometrial Cancer
Interventions
anti-PD1 agent therapy - 1 year, anti-PD1 agent therapy - 2 years
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Cary, North Carolina • Chapel Hill, North Carolina • Garner, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Recruiting Phase 1 Interventional

Study of XB010 in Subjects With Solid Tumors

NCT06545331
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
XB010, Pembrolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

NCT03126630
View directory record Official record
Conditions
Pleural Malignant Mesothelioma
Interventions
Anetumab Ravtansine, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

NCT06422143
View directory record Official record
Conditions
Non-small Cell Lung Cancer, NSCLC
Interventions
Pembrolizumab, sac-TMT, Carboplatin, Paclitaxel, Nab-paclitaxel
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
851 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
22
States / cities
Little Rock, Arkansas • Burbank, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

NCT07195695
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
Zongertinib, Pembrolizumab, Atezolizumab, Durvalumab, Nivolumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
27
States / cities
Fresno, California • Glendale, California • Orange, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

NCT07743190
View directory record Official record
Conditions
Triple Negative Breast Cancer (TNBC), Elevated Tumor-Infiltrating Lymphocytes
Interventions
Carboplatin, Paclitaxcel, Pembrolizumab
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2034
U.S. locations
2
States / cities
Syracuse, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Active, not recruiting No phase listed Observational

Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases

NCT07485179
View directory record Official record
Conditions
Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
Initiation of pembrolizumab, Initiation of chemotherapy
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)

NCT06170788
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Supportive care measures
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
15
States / cities
Phoenix, Arizona • Burbank, California • Grand Junction, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Not yet recruiting Phase 1 Interventional

Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal Cancer

NCT07772882
View directory record Official record
Conditions
Platinum Resistant Ovarian Cancer, Fallopian Tube Cancers, Peritoneal Carcinoma
Interventions
(Arginaid®) Oral Arginine, (R-Gene® 10) IV Arginine, Pembrolizumab, Bevacizumab, Paclitaxel, oral phosphamide
Drug
Lead sponsor
Rebecca Arend
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Recruiting Phase 3 Interventional

A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

NCT06452277
View directory record Official record
Conditions
Advanced Non-small Cell Lung Cancer, HER2 Mutation
Interventions
Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
444 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
25
States / cities
Newport Beach, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Recruiting Phase 2 Interventional

Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

NCT07770100
View directory record Official record
Conditions
Head and Neck Cancer, Non-Small Cell Lung Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer (GC)
Interventions
Stereotactic Body Radiation Therapy (SBRT), Pembrolizumab, Nivolumab, Atezolizumab, Ipilimumab
Radiation · Drug
Lead sponsor
Mark Bernard
Other
Eligibility
18 Years to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 5:57 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585
View directory record Official record
Conditions
Breast Cancer
Interventions
Dato-DXd, Durvalumab, Capecitabine, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
88
States / cities
Gilbert, Arizona • Tucson, Arizona • Hot Springs, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 25, 2026, 5:57 PM EDT

About this Pembrolizumab clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Pembrolizumab as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Pembrolizumab.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Pembrolizumab.